Our long-term goal is to develop vaccines and antiviral treatments for Ebolavirus infections. We have developed biologically contained Ebolaviruses that protect mice against challenge with a lethal dose of mouse-adapted Ebolavirus.
In Aim 1, we plan to test the protective efficacy of these Ebolaviruses in guinea pigs and nonhuman primates. Towards drug development, we have established three different highthroughput screening systems that allow screening in BSL-2 containment.
In Aim 2, we propose to conduct high-throughput screening and to optimize lead compounds. The lack of effective preventive or therapeutic treatments for Ebolavirus infections is partly due to the lack of knowledge of cellular genes involved in Ebolavirus replication. Our pilot study demonstrated the potential of siRNA screening approaches to identify such genes;therefore, we plan to conduct siRNA screening of commercially available human siRNA libraries to identify critical genes for the Ebolavirus life cycle (Aim 3). Candidate genes/gene products will then be characterized to elucidate the mechanism(s) by which they interfere with Ebolavirus replication. Studies in Aim 3 may thus suggest novel approaches to the treatment of Ebolavirus infections.

Public Health Relevance

The long-term goal of this research is to develop vaccines and antiviral treatments for Ebolavirus infections. Currently, neither preventative nor therapeutic treatments are available for Ebolavirus infections, making their development an urgent task.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI057153-10
Application #
8448668
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
2013-03-01
Project End
2014-02-28
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
10
Fiscal Year
2013
Total Cost
$224,792
Indirect Cost
$73,093
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Hoang, Ky V; Rajaram, Murugesan V S; Curry, Heather Marie et al. (2018) Complement Receptor 3-Mediated Inhibition of Inflammasome Priming by Ras GTPase-Activating Protein During Francisella tularensis Phagocytosis by Human Mononuclear Phagocytes. Front Immunol 9:561
Chen, Grischa Y; McDougal, Courtney E; D'Antonio, Marc A et al. (2017) A Genetic Screen Reveals that Synthesis of 1,4-Dihydroxy-2-Naphthoate (DHNA), but Not Full-Length Menaquinone, Is Required for Listeria monocytogenes Cytosolic Survival. MBio 8:
Sloup, Rudolph E; Konal, Ashley E; Severin, Geoffrey B et al. (2017) Cyclic Di-GMP and VpsR Induce the Expression of Type II Secretion in Vibrio cholerae. J Bacteriol 199:
Kant, Sashi; Asthana, Shailendra; Missiakas, Dominique et al. (2017) A novel STK1-targeted small-molecule as an ""antibiotic resistance breaker"" against multidrug-resistant Staphylococcus aureus. Sci Rep 7:5067
Coulson, Garry B; Johnson, Benjamin K; Zheng, Huiqing et al. (2017) Targeting Mycobacterium tuberculosis Sensitivity to Thiol Stress at Acidic pH Kills the Bacterium and Potentiates Antibiotics. Cell Chem Biol 24:993-1004.e4
Mitchell, Anthony; Tam, Christina; Elli, Derek et al. (2017) Glutathionylation of Yersinia pestis LcrV and Its Effects on Plague Pathogenesis. MBio 8:
Hollands, Andrew; Corriden, Ross; Gysler, Gabriela et al. (2016) Natural Product Anacardic Acid from Cashew Nut Shells Stimulates Neutrophil Extracellular Trap Production and Bactericidal Activity. J Biol Chem 291:13964-73
Kuhn, Misty L; Alexander, Evan; Minasov, George et al. (2016) Structure of the Essential Mtb FadD32 Enzyme: A Promising Drug Target for Treating Tuberculosis. ACS Infect Dis 2:579-591
Duckworth, Benjamin P; Wilson, Daniel J; Aldrich, Courtney C (2016) Measurement of Nonribosomal Peptide Synthetase Adenylation Domain Activity Using a Continuous Hydroxylamine Release Assay. Methods Mol Biol 1401:53-61
Park, Sung Ryeol; Tripathi, Ashootosh; Wu, Jianfeng et al. (2016) Discovery of cahuitamycins as biofilm inhibitors derived from a convergent biosynthetic pathway. Nat Commun 7:10710

Showing the most recent 10 out of 516 publications